ReviewKidney international2008
The mortality risk associated with higher hemoglobin: is the therapy to blame?
Review in Kidney international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 21 citations in OpenAlex.
- Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease.Frontiers in pharmacology · 2023Article
- Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study.Clinical kidney journal · 2021Article
- Clinical factors and the decision to transfuse chronic dialysis patients.Clinical journal of the American Society of Nephrology : CJASN · 2013Article
- Nonthyroidal illness and the cardiorenal syndrome.Nature reviews. Nephrology · 2013Review
- Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects.Hippokratia · 2011Article
- Carbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.Muscle & nerve · 2011Article
- Use of agents stimulating erythropoiesis in digestive diseases.World journal of gastroenterology · 2009Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent trials have demonstrated a trend for increased mortality when patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD) are treated with erythropoietin-stimulating agents (ESAs) to hemoglobin levels higher than recommended (>13 g/dl). Recent studies suggest that higher doses of ESAs, in themselves, may be at least partly responsible for this mortality risk. This is important, as more than 90% of patients with ESRD and approximately 20% of patients with CKD receive ESAs. Two new studies address this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.